Search research articles
Contact Us
Filters
Showing results (1-10 of 161) with videos related to
Page
of 17
Sort By:
Current Opinion in Oncology
|
March 27, 2015
What have we learned from exceptional tumour responses?: Review and perspectives
Niven Mehra, David Lorente, Johann S de Bono
Expert Review of Molecular Diagnostics
|
June 22, 2017
Molecular biomarkers to guide precision medicine in localized prostate cancer
Minke Smits, Niven Mehra, Michiel Sedelaar, et al.
Critical Reviews in Clinical Laboratory Sciences
|
October 26, 2023
Therapeutic biomarkers in metastatic castration-resistant prostate cancer: does the state matter?
Peter H J Slootbeek, Sofie H Tolmeijer, Niven Mehra, et al.
Science Advances
|
October 1, 2020
Probing single-cell metabolism reveals prognostic value of highly metabolically active circulating stromal cells in prostate cancer
Francesca Rivello, Kinga Matuła, Aigars Piruska, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 15, 2015
CCR 20th Anniversary Commentary: Circulating Tumor Cells in Prostate Cancer
Niven Mehra, Zafeiris Zafeiriou, David Lorente, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 27, 2007
Circulating mitochondrial nucleic acids have prognostic value for survival in patients with advanced prostate cancer
Niven Mehra, Maarten Penning, Jolanda Maas, et al.
Cancer Chemotherapy and Pharmacology
|
February 21, 2020
The impact of patient characteristics on enzalutamide pharmacokinetics and how this relates to treatment toxicity and efficacy in metastatic prostate cancer patients
Guillemette E Benoist, Inge M van Oort, David M Burger, et al.
Cancer Treatment and Research Communications
|
April 18, 2025
Pembrolizumab after platinum-based chemotherapy for metastatic urothelial cancer: comparison between patients from a Dutch nationwide cohort and KEYNOTE-045
Anke Richters, Britt Suelmann, Mira Franken, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
December 16, 2017
Comparison of Timed Automata with Discrete Event Simulation for Modeling of Biomarker-Based Treatment Decisions: An Illustration for Metastatic Castration-Resistant Prostate Cancer
Koen Degeling, Stefano Schivo, Niven Mehra, et al.
Cancer Letters
|
September 9, 2023
PARPing up the right tree; an overview of PARP inhibitors for metastatic castration-resistant prostate cancer
Peter H J Slootbeek, Joanneke K Overbeek, Marjolijn J L Ligtenberg, et al.
Page
of 17
Search research articles
Search
Showing results (1-10 of 161) with videos related to
Sort By:
Page
of 17
Current Opinion in Oncology
|
March 27, 2015
What have we learned from exceptional tumour responses?: Review and perspectives
Niven Mehra, David Lorente, Johann S de Bono
Expert Review of Molecular Diagnostics
|
June 22, 2017
Molecular biomarkers to guide precision medicine in localized prostate cancer
Minke Smits, Niven Mehra, Michiel Sedelaar, et al.
Critical Reviews in Clinical Laboratory Sciences
|
October 26, 2023
Therapeutic biomarkers in metastatic castration-resistant prostate cancer: does the state matter?
Peter H J Slootbeek, Sofie H Tolmeijer, Niven Mehra, et al.
Science Advances
|
October 1, 2020
Probing single-cell metabolism reveals prognostic value of highly metabolically active circulating stromal cells in prostate cancer
Francesca Rivello, Kinga Matuła, Aigars Piruska, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 15, 2015
CCR 20th Anniversary Commentary: Circulating Tumor Cells in Prostate Cancer
Niven Mehra, Zafeiris Zafeiriou, David Lorente, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 27, 2007
Circulating mitochondrial nucleic acids have prognostic value for survival in patients with advanced prostate cancer
Niven Mehra, Maarten Penning, Jolanda Maas, et al.
Cancer Chemotherapy and Pharmacology
|
February 21, 2020
The impact of patient characteristics on enzalutamide pharmacokinetics and how this relates to treatment toxicity and efficacy in metastatic prostate cancer patients
Guillemette E Benoist, Inge M van Oort, David M Burger, et al.
Cancer Treatment and Research Communications
|
April 18, 2025
Pembrolizumab after platinum-based chemotherapy for metastatic urothelial cancer: comparison between patients from a Dutch nationwide cohort and KEYNOTE-045
Anke Richters, Britt Suelmann, Mira Franken, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
December 16, 2017
Comparison of Timed Automata with Discrete Event Simulation for Modeling of Biomarker-Based Treatment Decisions: An Illustration for Metastatic Castration-Resistant Prostate Cancer
Koen Degeling, Stefano Schivo, Niven Mehra, et al.
Cancer Letters
|
September 9, 2023
PARPing up the right tree; an overview of PARP inhibitors for metastatic castration-resistant prostate cancer
Peter H J Slootbeek, Joanneke K Overbeek, Marjolijn J L Ligtenberg, et al.
Page
of 17